日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Vascular Endothelial Cell Growth Factor A Acts via Platelet-Derived Growth Factor Receptor α To Promote Viability of Cells Enduring Hypoxia

血管内皮细胞生长因子 A 通过血小板衍生的生长因子受体 α 发挥作用,促进耐缺氧细胞的活力

Steven Pennock, Leo A Kim, Andrius Kazlauskas

Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy

血管内皮生长因子主要通过血小板衍生的生长因子受体α起作用,促进增生性玻璃体视网膜病变

Steven Pennock, Luis J Haddock, Shizuo Mukai, Andrius Kazlauskas

Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease

雷珠单抗是一种潜在的预防增生性玻璃体视网膜病变的药物,增生性玻璃体视网膜病变是一种非血管生成性致盲疾病

Steven Pennock, David Kim, Shizuo Mukai, Matthew Kuhnle, Dal W Chun, Joanne Matsubara, Jing Cui, Patrick Ma, David Maberley, Arif Samad, Robert J Van Geest, Sarit L Oberstein, Reinier O Schlingemann, Andrius Kazlauskas

Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses

血管内皮生长因子 A 竞争性抑制血小板衍生生长因子 (PDGF) 依赖的 PDGF 受体激活以及随后的信号传导事件和细胞反应

Steven Pennock, Andrius Kazlauskas